Anastasiya A. Porozova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anastasiya A. Porozova has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Arina V. Zinkina-Orikhan
BIOCAD
7 shared publications - Yulia N. Linkova
JSC BIOCAD
6 shared publications - Anna V. Eremeeva
BIOCAD
5 shared publications - Elena V. Parshina
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
4 shared publications - Irina Evgenievna Poverennova
Samara State Medical University
4 shared publications - Zoya Alexandrovna Goncharova
Rostov State Medical University, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Open AccessDivozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- Open Access
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 619-628
The impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS
Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess the dynamics of skin fibrosis according to the mRSS in SSD patients treated DIV with depending on gender, disease duration and initial lung function. Material and methods . A post hoc analysis of data from a 48-week randomized placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS was conducted. 151 patients with SS were randomized into groups treated with DIV (n=76) or Placebo (n=75). DIV was administered intravenously at 250 mg on weeks 0 and 2, and then at 500 mg once every 24 weeks. The efficacy of DIV compared to placebo in terms of reducing skin fibrosis according to the mRSS was evaluated in subgroups of patients formed by gender (female/male), disease duration at the time of therapy initiation (less than 3 years, from 3 to 5 years, and more than 5 years), as well as by initial lung function (forced vital capacity (FVC) % predicted ≥80%/Results . The average change in mRSS from baseline at week 48 in men was –6.1±2.1 in the DIV and 1.6±6.2 in Placebo (LS mean difference (LSMD) –7.5 (95% CI: –11.6; –3.4); p=0.0004). In the subgroup of women, the change in mRSS was –5.1±4.1 and –2.5±4.4 in the DIV and Placebo groups respectively (LSMD=–2.5 (95% CI: –4.0; –1.0); p=0.001). In patients with a SS duration of up to 3 years, the mRSS dynamics was the most pronounced: –5.6±4.0 in DIV compared to –0.7±6.0 in placebo (LSMD=–5.2 (95% CI: –7.4; –2.9); pConclusion . DIV is a promising and effective therapeutic option for all patients with SS, regardless of gender, although a more pronounced effect on reducing skin fibrosis can be expected in men. DIV therapy is appropriate at any SS duration, but the highest efficacy in terms of skin fibrosis is observed in patients with recently developed disease. A significant and marked reduction in skin score in patients with initially normal and reduced lung function defines the possibility of DIV therapy in a broad population of SS patients. This is promising for improving the visceral lesions prognosis during DIV therapy, especially in the case of early therapy.
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 619-628
Open AccessThe impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS
Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess the dynamics of skin fibrosis according to the mRSS in SSD patients treated DIV with depending on gender, disease duration and initial lung function. Material and methods . A post hoc analysis of data from a 48-week randomized placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS was conducted. 151 patients with SS were randomized into groups treated with DIV (n=76) or Placebo (n=75). DIV was administered intravenously at 250 mg on weeks 0 and 2, and then at 500 mg once every 24 weeks. The efficacy of DIV compared to placebo in terms of reducing skin fibrosis according to the mRSS was evaluated in subgroups of patients formed by gender (female/male), disease duration at the time of therapy initiation (less than 3 years, from 3 to 5 years, and more than 5 years), as well as by initial lung function (forced vital capacity (FVC) % predicted ≥80%/Results . The average change in mRSS from baseline at week 48 in men was –6.1±2.1 in the DIV and 1.6±6.2 in Placebo (LS mean difference (LSMD) –7.5 (95% CI: –11.6; –3.4); p=0.0004). In the subgroup of women, the change in mRSS was –5.1±4.1 and –2.5±4.4 in the DIV and Placebo groups respectively (LSMD=–2.5 (95% CI: –4.0; –1.0); p=0.001). In patients with a SS duration of up to 3 years, the mRSS dynamics was the most pronounced: –5.6±4.0 in DIV compared to –0.7±6.0 in placebo (LSMD=–5.2 (95% CI: –7.4; –2.9); pConclusion . DIV is a promising and effective therapeutic option for all patients with SS, regardless of gender, although a more pronounced effect on reducing skin fibrosis can be expected in men. DIV therapy is appropriate at any SS duration, but the highest efficacy in terms of skin fibrosis is observed in patients with recently developed disease. A significant and marked reduction in skin score in patients with initially normal and reduced lung function defines the possibility of DIV therapy in a broad population of SS patients. This is promising for improving the visceral lesions prognosis during DIV therapy, especially in the case of early therapy.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Open AccessDivozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 51-59
Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis
Objective. To assess the efficacy and safety of long-term treatment with divozilimab in patients with relapsing multiple sclerosis (MS). Material and methods. Study No. BCD-132-EXT enrolled patients with relapsing MS who had previously received divozilimab at a dose of 500 mg in a phase II and III studies. Taking into account the participation of patients in previous studies, the total treatment duration was 4 years. The efficacy assessment was carried out using parameters associated with relapses (annualized relapse rate (ARR), time to first relapse), parameters of magnetic resonance imaging of the brain, and also included evaluation of neurological deficit. Safety monitoring included evaluation of standard laboratory parameters and reporting of adverse events. Results. A total of 44 patients were enrolled in the study, of which 93.2% (41/44) patients completed 4 years of follow-up. During the BCD-132-EXT period, the proportion of relapse-free patients was 97.7%. Over the 4 years of observation, the ARR remained consistently low, with the overall ARR over 4 years of divozilimab treatment being 0.052 (95% CI 0.028; 0.097). The 6-month confirmed disability progression (CDP) during the treatment period was observed in 4.5% (n=2) of patients. Adverse reactions, most of which were mild to moderate in severity, were reported in 59.1% (n=26) of patients. The most common adverse reactions were decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, and infusion reactions. Conclusion. The obtained results indicate the maintenance of efficacy over 4 years of therapy with divozilimab. The safety profile of divozilimab was favorable and consistent with previously obtained data.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 51-59
Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis
Objective. To assess the efficacy and safety of long-term treatment with divozilimab in patients with relapsing multiple sclerosis (MS). Material and methods. Study No. BCD-132-EXT enrolled patients with relapsing MS who had previously received divozilimab at a dose of 500 mg in a phase II and III studies. Taking into account the participation of patients in previous studies, the total treatment duration was 4 years. The efficacy assessment was carried out using parameters associated with relapses (annualized relapse rate (ARR), time to first relapse), parameters of magnetic resonance imaging of the brain, and also included evaluation of neurological deficit. Safety monitoring included evaluation of standard laboratory parameters and reporting of adverse events. Results. A total of 44 patients were enrolled in the study, of which 93.2% (41/44) patients completed 4 years of follow-up. During the BCD-132-EXT period, the proportion of relapse-free patients was 97.7%. Over the 4 years of observation, the ARR remained consistently low, with the overall ARR over 4 years of divozilimab treatment being 0.052 (95% CI 0.028; 0.097). The 6-month confirmed disability progression (CDP) during the treatment period was observed in 4.5% (n=2) of patients. Adverse reactions, most of which were mild to moderate in severity, were reported in 59.1% (n=26) of patients. The most common adverse reactions were decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, and infusion reactions. Conclusion. The obtained results indicate the maintenance of efficacy over 4 years of therapy with divozilimab. The safety profile of divozilimab was favorable and consistent with previously obtained data.
- Open Access
- 30 July 2025
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 5 (2) , 28-39
Evidence synthesis in neuromyelitis optica spectrum disorders: modeling a clinical trial based on published data
Relevance. Optic neuromyelitis spectrum disorders are a severe orphan nosology for which the search for new highly effective therapeutic options is a priority area of medical care. At the same time, due to the nature of this group of diseases, conducting new clinical trials (CT) is significantly complicated not only by the long and complex recruitment of patients and the unethical nature of using a parallel control group without treatment, but also by conducting comparisons with a historical control group or indirect comparisons, for which planning the sample size in the CT for a new therapy option is a separate methodological task. Objective. The aim of this study was to estimate the power for the analysis of the primary endpoint in the single-arm BCD-132-6/AQUARELLE trial, which was planned to be performed using an adjusted indirect comparison (AIC) of the study drug divosilimab with published data on the placebo group in the randomized N-MOmentum trial. Materials and methods. Using the data of the studies identified using a systematic search, a meta-regression model was estimated for the dependence of the average annual relapse rate (ARR) on therapy (anti-CD20 or placebo), the assessment horizon, and baseline patient characteristics. According to its results, for the expected BCD-132-6/AQUARELLE population, a 6-month ARR of 0.116 (95 % CI: 0.030–0.212) was predicted for anti-CD20 therapy. Next, a stepwise effective sample size (ESS) simulation was performed in the divosilimab group with power assessment. Results. The expected ratio of the ARR of divosilimab and placebo at 6 months was 0.117 (90 % CI: 0.045–0.214) with-out weighting and 0.156 (90% CI: 0.050–0.315) after weighting (ESS). The minimum EES required to achieve a power of 90 % when testing the hypothesis of superiority in the ARR at 6 months for divosilimab therapy compared with placebo with a one-sided type I error probability of 0.05 is 35 people. Conclusion. The obtained results can be used to support the statistical inference of the BCD-132-6/AQUARELLE study.
- 30 July 2025
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 5 (2) , 28-39
Open AccessEvidence synthesis in neuromyelitis optica spectrum disorders: modeling a clinical trial based on published data
Relevance. Optic neuromyelitis spectrum disorders are a severe orphan nosology for which the search for new highly effective therapeutic options is a priority area of medical care. At the same time, due to the nature of this group of diseases, conducting new clinical trials (CT) is significantly complicated not only by the long and complex recruitment of patients and the unethical nature of using a parallel control group without treatment, but also by conducting comparisons with a historical control group or indirect comparisons, for which planning the sample size in the CT for a new therapy option is a separate methodological task. Objective. The aim of this study was to estimate the power for the analysis of the primary endpoint in the single-arm BCD-132-6/AQUARELLE trial, which was planned to be performed using an adjusted indirect comparison (AIC) of the study drug divosilimab with published data on the placebo group in the randomized N-MOmentum trial. Materials and methods. Using the data of the studies identified using a systematic search, a meta-regression model was estimated for the dependence of the average annual relapse rate (ARR) on therapy (anti-CD20 or placebo), the assessment horizon, and baseline patient characteristics. According to its results, for the expected BCD-132-6/AQUARELLE population, a 6-month ARR of 0.116 (95 % CI: 0.030–0.212) was predicted for anti-CD20 therapy. Next, a stepwise effective sample size (ESS) simulation was performed in the divosilimab group with power assessment. Results. The expected ratio of the ARR of divosilimab and placebo at 6 months was 0.117 (90 % CI: 0.045–0.214) with-out weighting and 0.156 (90% CI: 0.050–0.315) after weighting (ESS). The minimum EES required to achieve a power of 90 % when testing the hypothesis of superiority in the ARR at 6 months for divosilimab therapy compared with placebo with a one-sided type I error probability of 0.05 is 35 people. Conclusion. The obtained results can be used to support the statistical inference of the BCD-132-6/AQUARELLE study.
- Open Access
- 1 May 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (2) , 158-167
The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods. Patients with SS according to ACR/EULAR (American College of Rheumatology/ European Alliance of Associations for Rheumatology) 2013 criteria with modified Rodnan skin score (mRSS) ≥10 and ≲20 and forced vital capacity (FVC) ≥40% from the due took part in the study. Infusions of DIV 250 mg were administered on weeks 0 and 2, and DIV 500 mg – on week 24 with the subsequent use in open mode, starting from week 48. This publication presents data obtained for 48 weeks of trial (before the DIV infusion at week 48). Primary endpoint was the change in the mRSS from baseline to week 48. The dynamic of FVC was estimated as the secondary endpoint. The safety evaluation included the frequency and profile of adverse events and adverse reactions (ARs). Immunogenicity was assessed by detection of binding and neutralizing anti-drug antibodies on weeks 2, 24 and 48.Results. 151 patients were randomized into two groups: DIV (n=76) and Placebo (n=75). The most were female; the median duration of the disease was about 3–4 years. The initial value of the mRSS was 14 and 13 points in DIV and PBO groups, respectively. The change of mRSS from baseline to week 48 was –5.8±1.1 points in DIV group and –2.7±1.0 points in Placebo group (adjusted mean difference (AMD) with 95% confidence interval –3.1 (–4.5; –1.7); pConclusion. Divosilimab has demonstrated a significant decrease in severity of skin fibrosis, a positive effect on the respiratory function and a favorable safety profile, which allows to consider it as a promising therapeutic option for SS.
- 1 May 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (2) , 158-167
Open AccessThe efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods. Patients with SS according to ACR/EULAR (American College of Rheumatology/ European Alliance of Associations for Rheumatology) 2013 criteria with modified Rodnan skin score (mRSS) ≥10 and ≲20 and forced vital capacity (FVC) ≥40% from the due took part in the study. Infusions of DIV 250 mg were administered on weeks 0 and 2, and DIV 500 mg – on week 24 with the subsequent use in open mode, starting from week 48. This publication presents data obtained for 48 weeks of trial (before the DIV infusion at week 48). Primary endpoint was the change in the mRSS from baseline to week 48. The dynamic of FVC was estimated as the secondary endpoint. The safety evaluation included the frequency and profile of adverse events and adverse reactions (ARs). Immunogenicity was assessed by detection of binding and neutralizing anti-drug antibodies on weeks 2, 24 and 48.Results. 151 patients were randomized into two groups: DIV (n=76) and Placebo (n=75). The most were female; the median duration of the disease was about 3–4 years. The initial value of the mRSS was 14 and 13 points in DIV and PBO groups, respectively. The change of mRSS from baseline to week 48 was –5.8±1.1 points in DIV group and –2.7±1.0 points in Placebo group (adjusted mean difference (AMD) with 95% confidence interval –3.1 (–4.5; –1.7); pConclusion. Divosilimab has demonstrated a significant decrease in severity of skin fibrosis, a positive effect on the respiratory function and a favorable safety profile, which allows to consider it as a promising therapeutic option for SS.
- Open Access
- 14 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 44-48
Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.
- 14 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 44-48
Open AccessEfficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.
- 27 February 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (2) , 52-59
Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results
Objective. To assess the efficacy and safety of sampeginterferon-β1a (samPEG-IFN-β1a) 180 μg and 240 μg administered once every 2 weeks compared to placebo and low dose interferon beta-1a (LIB) 30 μg administered once weekly. Material and methods. Patients with relapsing-remitting multiple sclerosis aged 18—60 years, with Expanded Disability Status Scale score ≤5.5 were randomized at a ratio of 2:2:2:1 to the following groups: samPEG-IFN-β1a 180 µg, samPEG-IFN-β1a 240 µg, LIB, placebo. After 20 weeks, the placebo group completed the study. After week 52, the final analysis was performed, which included the primary endpoint analysis, the LIB group patients completed their participation in the study. The patients in samPEG-IFN-β1a groups continued to receive therapy with samPEG-IFN-β1a 240 µg until week 100 inclusive. The results of the final analysis after 52 weeks have been previously published. The current article presents a long-term efficacy and safety of samPEG-IFN-β1a after 104 weeks of the trial. Results. The annualized relapse rate over the second year was 0.16 in the samPEG-IFN-β1a 180 μg group and 0.09 in the samPEG-IFN-β1a 240 μg group. By week 104, the proportion of relapse-free patients was 77.0% (87/113) and 83.3% (95/114) in the samPEG-IFN-β1a 180 μg and 240 μg groups, respectively. There were no negative dynamics of MRI markers, neurological deficit parameters and cognitive functions by scales and tests. The safety profile of samPEG-IFN-β1a was consistent with the known safety profile of IFN-β therapy. Conclusion. Treatment with samPEG-IFN-β1a is an effective and safe first-line therapy for relapsing-remitting multiple sclerosis patients.
- 27 February 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (2) , 52-59
Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results
Objective. To assess the efficacy and safety of sampeginterferon-β1a (samPEG-IFN-β1a) 180 μg and 240 μg administered once every 2 weeks compared to placebo and low dose interferon beta-1a (LIB) 30 μg administered once weekly. Material and methods. Patients with relapsing-remitting multiple sclerosis aged 18—60 years, with Expanded Disability Status Scale score ≤5.5 were randomized at a ratio of 2:2:2:1 to the following groups: samPEG-IFN-β1a 180 µg, samPEG-IFN-β1a 240 µg, LIB, placebo. After 20 weeks, the placebo group completed the study. After week 52, the final analysis was performed, which included the primary endpoint analysis, the LIB group patients completed their participation in the study. The patients in samPEG-IFN-β1a groups continued to receive therapy with samPEG-IFN-β1a 240 µg until week 100 inclusive. The results of the final analysis after 52 weeks have been previously published. The current article presents a long-term efficacy and safety of samPEG-IFN-β1a after 104 weeks of the trial. Results. The annualized relapse rate over the second year was 0.16 in the samPEG-IFN-β1a 180 μg group and 0.09 in the samPEG-IFN-β1a 240 μg group. By week 104, the proportion of relapse-free patients was 77.0% (87/113) and 83.3% (95/114) in the samPEG-IFN-β1a 180 μg and 240 μg groups, respectively. There were no negative dynamics of MRI markers, neurological deficit parameters and cognitive functions by scales and tests. The safety profile of samPEG-IFN-β1a was consistent with the known safety profile of IFN-β therapy. Conclusion. Treatment with samPEG-IFN-β1a is an effective and safe first-line therapy for relapsing-remitting multiple sclerosis patients.